Continuous Manufacturing Teed Up As Disrupting Force In Pharma Sector
This article was originally published in The Tan Sheet
The question studied over the past decade – whether the industry should adopt continuous manufacturing – has been answered, and the new question is how best to implement it? Pharma firms have drafted a survival guide as they take advantage of continuous manufacturing and realize how it can transform an industry rooted in batch processing.
You may also be interested in...
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.